Real world costs and cost-effectiveness of Rituximab for diffuse large B-cell lymphoma patients: a population-based analysis

BACKGROUND: Current treatment of diffuse-large-B-cell lymphoma (DLBCL) includes rituximab, an expensive drug, combined with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy. Economic models have predicted rituximab plus CHOP (RCHOP) to be a cost-effective alternative to...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Khor, Sara, Beca, Jaclyn, Krahn, Murray, Hodgson, David, Lee, Linda, Crump, Michael, Bremner, Karen E, Luo, Jin, Mamdani, Muhammad, Bell, Chaim M, Sawka, Carol, Gavura, Scott, Sullivan, Terrence, Trudeau, Maureen, Peacock, Stuart, Hoch, Jeffrey S
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2014
Teme:
Research Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4148552/
https://ncbi.nlm.nih.gov/pubmed/25117912
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-14-586
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items